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Abstract
Background: Evidence indicates a cross-regulation between two kinases, leucine-rich repeat kinase 2 (LRRK2)
and protein kinase A (PKA). In neurons, LRRK2 negatively regulates PKA activity in spiny projecting neurons during
synaptogenesis and in response to dopamine D1 receptor activation acting as an A-anchoring kinase protein
(AKAP). In microglia cells, we showed that LRRK2 kinase activity negatively regulates PKA, impacting NF-κB p50
signaling and the inflammatory response. Here, we explore the molecular mechanism underlying the functional
interaction between LRRK2 and PKA in microglia.
Methods: To understand which step of PKA signaling is modulated by LRRK2, we used a combination of in vitro
and ex vivo systems with hyperactive or inactive LRRK2 as well as different readouts of PKA signaling.
Results: We confirmed that LRRK2 kinase activity acts as a negative regulator of PKA activation state in microglia.
Specifically, we found that LRRK2 controls PKA by affecting phosphodiesterase 4 (PDE4) activity, modulating
cAMP degradation, content, and its dependent signaling. Moreover, we showed that LRRK2 carrying the G2019S
pathological mutation downregulates PKA activation causing a reduction of PKA-mediated NF-κB inhibitory
signaling, which results, in turn, in increased inflammation in LRRK2 G2019S primary microglia upon α-synuclein
pre-formed fibrils priming.
Conclusions: Overall, our findings indicate that LRRK2 kinase activity is a key regulator of PKA signaling and
suggest PDE4 as a putative LRRK2 effector in microglia. In addition, our observations suggest that LRRK2 G2019S
may favor the transition of microglia toward an overactive state, which could widely contribute to the progression
of the pathology in LRRK2-related PD.
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Background
Mutations in the leucine-rich repeat kinase 2 (LRRK2)
gene are linked to familial Parkinson’s disease (PD), and
common variants increase the lifetime risk for PD [1–3].
LRRK2 encodes a large multimeric protein characterized
by an enzymatic core with GTPase and serine/threonine
kinase activities and several domains surrounding these
two domains that are rich in repeats involved in the
assembly of signaling complexes [4]. Among all the
reported LRRK2 variants, seven missense mutations,
clustered within the enzymatic core of the protein,
clearly segregate with disease [5], with the G2019S sub-
stitution being by far the most frequent in both familial
and apparently sporadic PD cases [6]. The G2019S
mutation, located in the kinase domain, augments the
kinase activity of the protein as revealed by increased
S1292 auto-phosphorylation [7–9] and Rabs phosphoryl-
ation [10, 11].
LRRK2 is expressed in several brain regions, includ-
ing the substantia nigra pars compacta, striatum, hippo-
campus, cortex, and olfactory bulb [12, 13]. As well as
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neurons, LRRK2 is also expressed in astrocytes and
microglia [14], where it has been associated with in-
flammatory processes related to PD [15, 16]. In this
context, we recently demonstrated that microglia with
LRRK2 genetic deletion or kinase inhibition exhibit a
reduction of inflammation after lipopolysaccharide
(LPS) or α-synuclein pre-formed fibrils (α-Syn pffs)
priming. At the molecular level, we found that LRRK2
negatively regulates protein kinase A (PKA) activity,
triggering an increase of PKA-mediated phosphoryl-
ation and consequent accumulation of NF-κB inhibitory
subunit p50 in the nucleus, which ultimately leads to
repression of NF-κB target genes [17]. A cross-talk be-
tween LRRK2 and PKA has been reported also by others
[18–20]. Parisiadou and colleagues found that LRRK2 acts
as a negative modulator of PKA signaling in neurons,
observing that genetic deletion of LRRK2 causes increased
PKA-mediated phosphorylation of glutamate receptor
(GluR) 1, cAMP response element-binding protein
(CREB), and cofilin resulting in abnormal synaptogenesis
and transmission of striatal projection neurons [19]. Spe-
cifically, they found that LRRK2 interacts with PKA regu-
latory (R) IIβ subunit and that this interaction occurs
between LRRK2 Ras of complex proteins (ROC) domain
and PKA RIIβ dimerization domain. Moreover, they re-
ported that PKA RIIβ is mislocalized in the dendritic
spines of LRRK2 knock-out (KO) compared to wild-type
(WT) neurons, leading them to hypothesize that LRRK2
regulates PKA activity by acting as an A-anchoring kinase
protein (AKAP) or AKAP-like.
In its inactive form, PKA is a tetrameric enzyme com-
posed of a R subunit dimer and two catalytic (C) sub-
units. In the absence of cAMP, a dimer of R subunits
binds and suppresses the activity of two C subunits.
Conversely, the cooperative binding of cAMP to the R
subunits causes a conformational change that leads to
the activation of PKA and consequent phosphorylation
of its targets [21]. Typically, PKA is bound to scaffold
proteins called AKAPs, which play a critical role in the
compartmentalization of cAMP signaling by confining
PKA to specific subcellular locations and in physical
proximity to its targets [22]. PKA signaling is tightly
controlled also by additional regulatory proteins that
are part of the AKAP-PKA multiprotein complex, such
as cAMP-degrading phosphodiesterases (PDEs), im-
portant to regulate the magnitude and duration of PKA
activation, and phosphatases (PP), which dephosphory-
late PKA targets to terminate the signal [23].
Building on previous observations reported by us [17]
and others [19], in this study, we investigated the molecu-
lar mechanism underlying LRRK2-dependent regulation
of PKA signaling in microglia. We used a combination of
in vitro and ex vivo systems with hyperactive or inactive
LRRK2 as well as different readouts of PKA activity, such
as LRRK2-PKA RIIβ interaction and PKA RIIβ S114
phosphorylation, to evaluate the impact of LRRK2 on
PKA activation. AKAP-PKA RII interaction, PKA RII
phosphorylation, and regulation of cAMP content are key
events that regulate the on/off state of PKA [24]. Here,
we validated LRRK2 kinase activity as the negative
regulator of PKA activation state in microglia cells.
Moreover, we demonstrated that LRRK2 controls PKA
activity through regulation of PDE4, modulating cAMP
degradation, content, and its dependent signaling. We
further found that LRRK2 with G2019S pathological
mutation decreases PKA activity leading to a reduction
of PKA-mediated NF-κB inhibitory signaling with con-
sequent increase of inflammation in primary microglia
with LRRK2 G2019S after α-Syn pffs treatment.
Taken together, our results indicate that LRRK2 kinase
activity is a crucial regulator of PKA signaling in micro-
glia and propose PDE4 as a novel LRRK2 effector pro-
tein in these cells.
Materials and methods
Animals
All animal procedures were carried out in strict accord-
ance with the recommendations issued in the guide-
lines for the Care and Use of Laboratory Animals of the
National Institutes of Health (NIH) for animals housed
at NIH and for the European Community Council Direct-
ive 2010/63/UE for animals housed at the University of
Padova. The protocols were approved by the Institutional
Animal Care and Use Committees of the US National
Institute on Aging (approval number 463-LNG-2018) and
by the Ethics Committee of the University of Padova
(Project ID 1041/2016-PR), respectively.
Cell cultures
BV2 cells were cultured in RPMI-40 medium (Sigma
Aldrich) supplemented with 10% fetal bovine serum
(FBS), 2 mM glutamine, penicillin, and streptomycin.
HEK293T cells were cultured in Dulbecco modified Eagle
medium (DMEM, Life Technologies) supplemented
with 10% FBS, penicillin, and streptomycin. Primary
microglia cells were derived from postnatal days 1–4
(P1–4) LRRK2 wild-type and G2019S knock-in (KI)
mice as recently described [17]. Specifically, cerebral corti-
ces were mechanically dissociated in cold phosphate-buff-
ered saline (PBS, Sigma Aldrich), then cellular suspension
was allowed to settle for 5 min, and the top fraction was
collected, centrifuged for 5 min at 1000g, and
re-suspended in DMEM-F12, supplemented with 10%
FBS, 2 mM glutamine, 2 mM sodium pyruvate (Sigma
Aldrich), penicillin, and streptomycin. Cell suspension ob-
tained from three brains was plated on poly-L-lysine
(0.1 mg/ml, Sigma Aldrich)-coated T-75 flask. After 4 days,
the medium was replaced and the mixed glial culture was
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maintained until day 14. At 12 days, microglia cells were
isolated from the mixed culture by shaking for 4 h at
160 rpm, and the purity of the obtained culture was verified
by double immunofluorescence with mouse anti-CD11b
(Cell signaling #ab1211) for microglia cells and with rabbit
anti-GFAP (DAKO #Z0334) for astrocytes. The amount of
astrocyte contaminants was negligible.
All cells were maintained at 37 °C in a 5% CO2 con-
trolled atmosphere.
Plasmids and transfection
HEK293T cell transfections were performed using poly-
ethylenimine (Polysciences) following the manufacturer’s
recommendations. Eukaryotic expression constructs of
3xFlag-tagged LRRK2 WT and G2019S, green fluores-
cence protein (GFP)-tagged PKA RIIβ and GFP empty
vector, generated as described previously [19, 25], were
used for co-immunoprecipitation (co-IP) assays, while
plasmid of GFP-tagged LRRK2 WT, generated as reported
[26], was used for pull-down assays.
Compounds and treatments
During treatments, BV2 cells were cultured in medium
containing 1% FBS. LRRK2 inhibitor GSK2578215A
(GSK, Tocris Bioscience) and forskolin (Sigma Aldrich)
were used at 2 μM and 30 μM, respectively, for 90 min.
PDE4 inhibitor rolipram (Tocris Bioscience) was used at
10 μM for 30 min. Dimethyl sulfoxide (DMSO) was used
as control.
Production and aggregation of recombinant α-Syn
Human α-Syn pffs were generated from recombinant
α-Syn produced by a lipid A mutant of Escherichia coli,
BL21(DE3), with strongly reduced endotoxicity [27].
After purification, α-Syn was incubated for 15 days to in-
duce aggregation. α-Syn pffs were used at 25 μM for
24 h.
Cell and brain lysates and western blotting
BV2 cells and mouse brains were solubilized as recently
described [17]. Protein concentrations were determined
using the BCA protein concentration assay as per manu-
facturer’s instructions (Thermo Scientific). Fifty micro-
grams of total proteins was separated by electrophoresis
onto 4–20% SDS-PAGE gels and then transferred onto
Immobilon-P membrane. Subsequently, membranes were
incubated 1 h at room temperature (RT) with the follow-
ing antibodies: rabbit anti-LRRK2 MJFF2 (1:500, Abcam
#ab133474), rabbit anti-phospho S1292 LRRK2 (1:500,
Abcam #ab203181), rabbit anti-p105/p50 (1:2000, Cell
Signaling #13586S), rabbit anti-phospho S337 p50 (1:1000,
Santa Cruz #101744), anti-flag HRP (1:20.000, Sigma Al-
drich #A8592), anti-GFP (1:20.000, Roche #11814460001),
mouse anti-PKA RIIβ (1:1000, BD Biosciences #610625),
mouse anti-phospho S114 PKA RIIβ (1:1000, BD Bio-
sciences #612550), goat anti-IL-1β (1:2000, R&D system
#AF401NA), and mouse anti-GAPDH (1:10.000, Origene
#TA150046). Then, membranes were incubated 1 h at RT
with horseradish peroxidase (HRP)-conjugated secondary
antibodies (Sigma Aldrich) and finally incubated with ECL
western blot substrate (Thermo Scientific).
Co-immunoprecipitation and pull-down assays
HEK293T cells were harvested at 48 h post-transfection.
For co-IP assays, cells were lysed in lysis buffer (50 mM
Tris pH 7.5, 1% Triton X-100, 1 mM β-glycerophosphate,
5 mM sodium pyrophosphate, 50 mM sodium orthovana-
date, 0.27 M sucrose, 1 mM EDTA) and incubated with
anti-Flag M2 affinity gel (Sigma Aldrich) overnight. For
pull-down assays, tagged proteins were purified using
GFP-trap resin (CromoTek) and then incubated for 2 h
with cell lysates containing endogenous prey protein.
Immuno-complexes were washed three times with lysis
buffer supplemented with 0.25 M NaCl, resuspended in
sample buffer, and then subjected to immunoblotting
analysis.
RNA extraction and sequencing
After shaking, isolated microglia cells were seeded for
2 days and then collected for RNA extraction, which
was performed as previously described [17]. RNA qual-
ity was estimated using an Agilent 2100 Bioanalyzer
RNA 6000 Nano Chip (Agilent). Samples had a mean
RIN of 9. We purified RNA depleted of rRNA starting
from 1 μg total RNA, then synthesized cDNA libraries
using TruSeq stranded Total RNA library prep kit
(Illumina, RS-122-9008) following the manufacturer’s in-
structions (https://support.illumina.com/content/dam/illu
mina-support/documents/documentation/chemistry_docu
mentation/samplepreps_truseq/truseqstrandedtotalrna/tru
seq-stranded-total-rna-sample-prep-ls-euc-ltf-15031060-e.
pdf). Before sequencing, cDNA libraries were quantified
by digital PCR using the ddPCR Library quantification kit
(Biorad). Subsequently, cDNA libraries were multiplexed
with four samples per pool and 7 pM of each pool hybrid-
ized to a flow cell following cluster generation using an
Illumina cluster station. Libraries were sequenced on Illu-
mina HiSeq2500 (Illumina) to generate ~ 35 million of
100-bp single-end reads per library.
cAMP ELISA
cAMP levels were quantified by using cAMP Elisa kit
(Enzo Life Science, #ADI-900-163) according to the
manufacturer’s protocol. Specifically, BV2 cells were first
treated with 2 μM LRRK2 GSK inhibitor or DMSO for
90 min and then with 30 μM forskolin for 15 min to
enhance cAMP contents. Five independent samples for
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each condition, assayed in two technical replicates, were
used for the analysis.
Statistical analysis
All quantitative data are expressed as mean ± SEM and
represent at least three independent sets of experiments.
Statistical significance of differences between two groups
was assessed by unpaired t test or one-sample t test,
while for multiple comparisons by one-way ANOVA
with Tukey’s post hoc test. Data were analyzed using
Prism (GraphPad).
Results
LRRK2G2019S KI brain lysates exhibit reduced level of PKA-
mediated NF-κB p50 phosphorylation
We recently demonstrated that loss of LRRK2 or
inhibition of its kinase activity results in increased
PKA-dependent phosphorylation of NF-κB p50 inhibi-
tory subunit at S337 [17], crucial to repress NF-κB target
genes in the absence of extracellular stimulation [28]. To
confirm that this regulation depends on LRRK2 kinase
activity, we also explored the effect of the hyperactive
LRRK2-G2019S mutation on NF-κB p50 phosphoryl-
ation. In agreement with results using LRRK2 genetic
deletion or kinase activity inhibition, brain lysates from
LRRK2G2019S KI mice exhibited 50% reduced S337 phos-
phorylation compared to WT mice (Fig. 1). Moreover,
as expected, LRRK2G2019S KI brains display approxi-
mately fourfold enhanced kinase activity compared to
WT mice, as measured by S1292 auto-phosphorylation
(Fig. 1). Taken together, these results demonstrate that
LRRK2 controls PKA activation state through its kinase
activity.
LRRK2 kinase activity controls LRRK2-PKA RIIβ interaction
LRRK2 has been reported to bind PKA RIIβ subunit
and to negatively regulate PKA signaling in neurons
in an AKAP-like manner [19]. Starting from these ob-
servations, we investigated whether LRRK2 also inter-
acts with PKA RIIβ in microglia. To this end, we first
validated in our hands LRRK2 interaction with PKA
RIIβ by co-IP using transfected HEK293T cells. As
shown in Fig. 2a, 3xFlag-LRRK2 WT interacts with
GFP-PKA RIIβ but not with GFP, confirming previous
findings. Next, we examined whether LRRK2 also in-
teracts with endogenous PKA RIIβ in microglia cells.
Purified GFP-LRRK2 WT, but not GFP control pro-
tein, pulls down endogenous PKA RIIβ subunit from
microglial lysates (Fig. 2b), supporting the notion that
this interaction occurs in different cell types.
Our results indicate that LRRK2 kinase activity influ-
ences PKA activation state. To address the underlining
mechanism, we assessed whether LRRK2 kinase activity
impacts LRRK2 binding to PKA RIIβ subunit. To this
end, we first analyzed the interaction by co-IP upon
co-transfection of 3xFlag-LRRK2 WT or 3xFlag-LRRK2
G2019S with GFP-PKA RIIβ in HEK293T cells. We
found that LRRK2 with the G2019S mutation interacts
more efficiently with PKA RIIβ compared to LRRK2
WT (Fig. 2c). Consistent with this idea, when we
analyzed the interaction of co-transfected proteins in
HEK293T cells after treatment with LRRK2 kinase
inhibitor GSK, we observed a significant reduction of
LRRK2-PKA RIIβ binding compared to cells treated
with DMSO (Fig. 2d). Since our findings indicate that
LRRK2 kinase inhibition activates PKA signaling, we
next examined whether forskolin, an activator of
Fig. 1 LRRK2G2019S KI brain lysates exhibit reduced level of PKA-mediated NF-κB p50 phosphorylation. LRRK2 WT and LRRK2G2019S KI brain lysates
were subjected to immunoblotting using NF-κB P-p50, total p50, P-LRRK2, and total LRRK2 antibodies. Quantification of P-p50 subunit is
normalized for total p50 protein. Quantification of P-LRRK2 is normalized for total LRRK2 protein. Data are representative of four animals (bars
represent the mean ± SEM; unpaired t test; *p < 0.05, **p < 0.01)
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adenylyl cyclase and indirectly of PKA, could pheno-
copy the interaction. Similar to GSK, forskolin treat-
ment reduces LRRK2-PKA RIIβ binding (Fig. 2d),
suggesting that when PKA is active, RIIβ has a lower
affinity for LRRK2. Finally, we confirmed the reduced
binding in the presence of LRRK2 kinase inhibition also
by pull-down assays from microglia cells. As reported
in Fig. 2, pull-down assays of GFP-LRRK2 incubated
with microglial lysates previously treated with GSK
inhibitor showed a reduction of interaction with
endogenous PKA RIIβ compared to microglia treated
with DMSO (Fig. 2e). Taken together, these results
demonstrate that LRRK2 kinase activity regulates
LRRK2-PKA RIIβ interaction as well as PKA activation
in microglia.
LRRK2 kinase activity affects PKA RIIβ phosphorylation at
S114
Phosphorylation of RIIβ-S114, together with the regu-
lation of cAMP content and the interaction between
AKAP and PKA RIIβ, is a key event required to regu-
late PKA signaling [24]. Specifically, S114-RIIβ is
de-phosphorylated by PPs when the C subunits are ac-
tive and then re-phosphorylated by PKA catalytic sub-
units as a feedback regulation to inhibit the enzyme
complex [24]. In the attempt of understanding which
step of the PKA signaling LRRK2 affects, we explored
the phosphorylation state of RIIβ using in vitro and ex
vivo systems with hyperactive or inactive LRRK2. First,
we evaluated RIIβ S114 phosphorylation in brain ly-
sates from LRRK2G2019S KI mice and found it is more
phosphorylated compared to WT brain lysates (Fig. 3a).
This result is in agreement with the observed enhance-
ment of LRRK2-PKA RIIβ interaction and with the
reduced PKA-dependent phosphorylation of p50, all in-
dicative of an inhibition of PKA activity in the presence
of LRRK2 G2019S mutation.
We subsequently examined S114-RIIβ phosphorylation
in brain lysates with LRRK2 genetic deletion (Fig. 3b)
and confirmed the data in microglia with LRRK2 kinase
inhibition (Fig. 3c). Consistent with observations with
the G2019S mutation, brain lysates from LRRK2 KO
mice (Fig. 3b) and BV2 cells treated with GSK inhibitor
(Fig. 3c) showed decreased levels of RIIβ phosphoryl-
ation at S114. Notably, treatment with forskolin pheno-
copies the effects of LRRK2 pharmacological inhibition
on S114-RIIβ (Fig. 3c), further indicating that inhibition
of LRRK2 activity results in increased PKA activation.
These results indicate that LRRK2 kinase activity affects
S114 phosphorylation of RIIβ and suggest that LRRK2
might control a downstream regulatory protein of PKA
signaling.
Fig. 2 LRRK2 kinase activity regulates LRRK2-PKA RIIβ interaction. a Cell lysates from HEK293T co-transfected with 3xFlag LRRK2 WT and GFP-PKA
RIIβ or GFP-empty vector were subjected to co-IP with anti-Flag M2 affinity gel, followed by Flag and GFP immunoblotting. b Pull-down assays
of purified GFP-LRRK2 WT or GFP-empty vector incubated with BV2 lysates were subjected to immunoblotting with GFP and PKA RIIβ antibodies.
c Cells lysates from HEK293T co-transfected with 3xFlag LRRK2 WT or 3xFlag LRRK2 G2019S and GPF-PKA RIIβ were subjected to co-IP with anti-
Flag M2 affinity gel, followed by Flag, GFP, and P-LRRK2 immunoblotting. Quantification LRRK2- RIIβ interaction has been obtained by normalization of
RIIβ for LRRK2 protein. Data are representative of three independent experiments (bars represent the mean ± SEM; unpaired t test; *p < 0.05). d Cell
lysates from HEK293T co-transfected with 3xFlag LRRK2 WT and GFP-empty vector or 3xFlag LRRK2 WT and GPF- PKA RIIβ treated with GSK, forskolin
(Forsk), or DMSO as control (CTR) were subjected to co-IP with anti-Flag M2 affinity gel, followed by Flag and GFP immunoblotting. Quantification
LRRK2-RIIβ interaction has been obtained by normalization of RIIβ for LRRK2 protein. Data are representative of four independent experiments (bars
represent the mean ± SEM; one-way ANOVA with Tukey’s post-test; **p < 0.01). e Pull-down assays of purified GFP-LRRK2 WT incubated with BV2
lysates previously treated with GSK or DMSO as control (CTR) were subjected to immunoblotting with GFP and PKA RIIβ antibodies. Quantification
LRRK2-RIIβ interaction has been obtained by normalization of RIIβ for LRRK2 protein. Data are representative of five independent experiments (bars
represent the mean ± SEM; unpaired t test; *p < 0.05)
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LRRK2 kinase activity controls cAMP levels through PDE4
The cAMP-PKA pathway is highly compartmentalized
and spatiotemporally controlled through the action of
PPs and PDEs signaling molecules. cAMP gradients are
shaped by action of specific PDEs, which degrade cAMP
and thus regulate the magnitude and duration of PKA
signaling [23]. Therefore, we decided to test the hypoth-
esis that LRRK2 may regulate PKA activation by control-
ling PDE-dependent cAMP degradation by quantifying
total cAMP directly in microglia cells after LRRK2 kin-
ase inhibition. Of interest, we found that cells treated
with GSK exhibit increased levels of cAMP compared to
cells treated with DMSO control (Fig. 4a), suggesting
that LRRK2 modulates PKA activation via regulation of
cAMP levels.
Cells express a defined subset of PDEs from 11 differ-
ent families, three of which specifically hydrolyze cAMP
(PDE4, PDE7, and PDE8) [29]. Accumulating literature
indicates that among all PDEs, the B-isoform of PDE4 is
the most highly expressed in immune cells, and, intri-
guingly, it has been proposed as a pharmacological
target to reduce neuroinflammation [30]. In support of
this notion, results from a RNA sequencing profile per-
formed on WT primary microglia cells reveal that
among the cAMP-specific PDEs, the PDE4B isoform is
the most expressed transcript in these cells (Fig. 4b).
Based on these observations, we focused our experi-
ments on PDE4. First, we explored whether PDE4 spe-
cifically regulates PKA signaling associated with NF-κB.
To this end, we analyzed PKA-dependent p50 phosphor-
ylation in BV2 microglia cells upon treatment with the
PDE4 inhibitor rolipram. We found that rolipram in-
creases the level of p50 phosphorylation compared to
cells treated with DMSO (Fig. 4c), confirming that PDE4
activity affects PKA signaling related to NF-κB p50.
Next, to test whether LRRK2 acts on PKA via PDE4, we
compared p50 phosphorylation of BV2 cells co-treated
with PDE4 and LRRK2 inhibitors or treated with PDE4
inhibitor alone. As shown in Fig. 4d, the combined treat-
ment of rolipram and GSK results in an increase of
NF-κB p50 phosphorylation similar to that produced by
rolipram alone, supporting the hypothesis that inhib-
ition of LRRK2 kinase activity increases cAMP levels
by inhibiting PDE4 activity.
LRRK2G2019S KI primary microglia exhibit increased levels
of pro-inflammatory IL-1β after priming with α-Syn pffs
We previously demonstrated that loss of LRRK2 or
inhibition of its kinase activity causes a reduction of
NF-κB-dependent transcription of inflammatory genes
after LPS or α-Syn pffs priming, which is mediated by
enhanced PKA activity and consequent increased
NF-κB p50 inhibitory signaling [17]. In addition, here,
we found that the G2019S pathological mutation re-
duces PKA signaling and NF-κB p50 inhibitory signal-
ing (Figs. 1, 2, and 3). Based on this, we next asked how
LRRK2 G2019S KI microglia cells would respond to an
inflammatory stimulus. We treated primary microglia
cells from LRRK2 WT or G2019S KI mice with α-Syn
pffs and quantified pro-inflammatory IL-1β precursor
(hereafter IL-1β) after 24 h of treatment. As shown in
Fig. 5, α-Syn pffs induce IL-1β expression in WT micro-
glia which is increased by about 65% in G2019S KI cells.
LRRK2 S1292 auto-phosphorylation is, as expected, in-
creased in G2019S KI microglia compared to WT cells
(Fig. 5). Taken together, these findings indicate that micro-
glia with LRRK2 G2019S exhibit an enhanced α-Syn
pffs-mediated inflammation caused, at least in part, by a
downregulation of cAMP/PKA signaling.
Discussion
Accumulating evidence indicates a functional interaction
between LRRK2 and PKA, although the precise molecular
mechanisms of this cross-talk still need to be elucidated
Fig. 3 LRRK2 kinase activity affects phosphorylation of PKA RIIβ at S114. a LRRK2 WT and LRRK2G2019S KI brain lysates were subjected to
immunoblotting using P-PKA RIIβ and total PKA RIIβ antibodies. Quantification of P-PKA RIIβ is normalized for total PKA RIIβ protein. Data are
representative of four animals (bars represent the mean ± SEM; unpaired t test; *p < 0.05). b LRRK2 WT and LRRK2 KO brain lysates were subjected
to immunoblotting using P-PKA RIIβ and total PKA RIIβ antibodies. Quantification of P-PKA RIIβ is normalized for total PKA RIIβ protein. Data are
representative of three animals (bars represent the mean ± SEM; unpaired t test; *p < 0.05). c BV2 cell lysates treated with GSK, forskolin (Forsk),
and DMSO as control (CTR) were subjected to immunoblotting using P-PKA RIIβ and total PKA RIIβ antibodies. Quantification of P-PKA RIIβ is
normalized for total PKA RIIβ protein. Data are representative of seven independent experiments (bars represent the mean ± SEM; one-way
ANOVA with Tukey’s post-test; *p < 0.05, **p < 0.01)
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[31]. In this study, using in vitro and ex vivo systems
with hyperactive or inactive LRRK2 and different read-
outs of PKA signaling, we validated LRRK2 kinase
activity as the negative regulator of PKA activation.
Specifically, we provided preliminary evidence that LRRK2
controls PKA activity by acting at level of PDE4, with im-
pact on cAMP degradation, content, and its dependent
signaling in microglia cells. Interestingly, we found that
LRRK2 with G2019S pathological mutation downregulates
PKA activity leading to an attenuation of PKA-mediated
NF-κB inhibitory signaling with consequent increment of
inflammation in microglia with LRRK2 G2019S KI after
α-Syn pffs priming.
The available literature supports the notion that the func-
tional interaction between LRRK2 and PKA may be bidirec-
tional. PKA can act upstream of LRRK2 through direct
phosphorylation of distinct LRRK2 serine residues [20, 32],
but also LRRK2 can operate upstream of PKA and nega-
tively regulate its activity [17, 19] with apparent different
mechanisms in neurons and microglia [31]. Neuronal
LRRK2 was suggested to act as an AKAP by tethering PKA
signaling at specific subcellular domains independent of its
kinase activity [19]. However, a very recent study by Tozzi
and colleagues hypothesized that G2019S mutation is posi-
tively associated with PKA signaling in striatal medium
spiny neurons [18], making the scenario even more compli-
cated. In contrast, in microglia cells, LRRK2 kinase activity
appears to be essential to regulate PKA activation/inactiva-
tion state. In support of this, we recently reported that
LRRK2 kinase inhibition or genetic deletion activates PKA
signaling [17]. Here we collected additional evidence that
LRRK2 carrying the hyperactive G2019S mutation results
in a downregulation of PKA pathway, further supporting a
model where is the kinase activity of LRRK2 and not the
presence of the protein itself to regulate PKA signaling in
microglia cells. Overall, these observations suggest that
LRRK2-dependent regulation of PKA activity might be
cell-type specific.
Fig. 4 LRRK2 kinase activity controls cAMP levels through PDE4. a Quantification of cAMP levels in BV2 cells treated with GSK or DMSO as control
(CTR). cAMP levels are normalized for total protein concentration in each sample. Data are representative of five independent experiments (bars
represent the mean ± SEM; unpaired t test; *p < 0.05). b Expression of cAMP-specific PDEs generated from a RNA sequencing profile performed
on WT primary microglia cells. Data are representative of five independent samples (bars represent the mean ± SEM; one-way ANOVA with
Tukey’s post-test; *p < 0.05, *** p < 0.001). c BV2 cell lysates treated with rolipram or DMSO as control (CTR) were subjected to immunoblotting
using NF-κB P-p50 and total p50 antibodies. Quantification of NF-κB P-p50 is normalized for total p50 protein. Data are representative of three
independent experiments (bars represent the mean ± SEM; unpaired t test; *p < 0.05). d BV2 cell lysates treated with rolipram, rolipram and GSK,
or DMSO as control (CTR) were subjected to immunoblotting using NF-κB P-p50 and total p50 antibodies. Quantification of NF-κB P-p50 is
normalized for total p50 protein. Data are representative of three independent experiments (bars represent the mean ± SEM; one-way ANOVA
with Tukey’s post-test; *p < 0.05)
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In this study, to investigate the molecular mechanism
underlying LRRK2-PKA cross-talk in microglia, we
started exploring LRRK2-PKA RIIβ interaction and
RIIβ phosphorylation state as readouts of PKA activa-
tion state in relation to LRRK2. Auto-phosphorylation
of S114-RIIβ, or S99-RIIα, by C subunits controls the
interaction between RII and C subunits [33] and the
binding with AKAP [34], all key events of the activation/
inactivation state of PKA. Specifically, the allosteric activa-
tion of PKA by cAMP results in the activation of C sub-
units, allowing the de-phosphorylation of RII dimer by
PPs and its subsequent dissociation from AKAPs. In con-
trast, degradation of cAMP by PDEs, re-phosphorylation
of RII dimer by the C subunits, and RII-AKAP re-binding
cooperate to inactivate PKA signaling [24]. Here, by
assessing LRRK2-PKA RIIβ interaction and RIIβ phos-
phorylation state, we found that LRRK2 G2019S interacts
more with RIIβ compared to the WT protein in cells and
brain lysates from LRRK2G2019S KI mice exhibit increased
phosphorylation of RIIβ compared to WT mice, suggest-
ing that LRRK2 G2019S plays an inhibitory effect on PKA
activation. In support of these results, LRRK2G2019S KI
mice displayed reduction of PKA-mediated NF-κB p50
phosphorylation, a well-established PKA phosphorylation
target [35], whereas loss of LRRK2 or its kinase inhibition
results in a decrease of LRRK2-RIIβ interaction and of
S114 RIIβ phosphorylation, diagnostic of an active PKA.
Taken together, these findings provide additional evidence
that LRRK2 kinase activity regulates PKA by affecting
S114 phosphorylation and the interaction with RIIβ
subunit.
To gain more insights into the molecular mechanism of
this regulation, we initially tested the hypothesis that
LRRK2 modulates PKA activity through direct phosphor-
ylation of RII subunits, but we did not find any convincing
evidence from in vitro kinase assays (unpublished obser-
vations). PKA is part of a multifunctional complex com-
posed of different signaling molecules, including PPs and
PDEs, which are essential for compartmentalization and
regulation of PKA activation state [36]. In particular, PDEs
play a crucial role in controlling the magnitude and the
duration of PKA signaling [37]. Given this key function
of PDEs and the established link between PDE4 and
inflammatory responses in microglia [38–41], we inves-
tigated whether LRRK2 activity affects cAMP levels in
microglia. We found that cells treated with LRRK2
kinase inhibitor exhibit increased levels of cAMP
compared to control cells, indicating that LRRK2 activ-
ity affects cAMP degradation. Moreover, by using
phospho-S337 NF-κB p50 as readout of PKA activity,
we were able to show that pharmacological manipula-
tion of PDE4 activity impacts PKA signaling associated
with NF-κB p50 phosphorylation. In addition, the com-
bined treatment of PDE4 and LRRK2 inhibitors results
in similar increase of NF-κB p50 phosphorylation com-
pared to cells treated with rolipram alone, suggesting
that LRRK2 kinase activity controls PDE4 inhibition.
Future experiments will be required to elucidate the
Fig. 5 LRRK2G2019S KI primary microglia exhibit increased level of pro-inflammatory IL-1β after α-Syn pffs priming. LRRK2 WT and G2019S KI
microglia lysates treated with 25 μM α-Syn pffs or PBS as control (CTR) were subjected to immunoblotting using P-LRRK2, total LRRK2, IL-1β, and
GAPDH antibodies. Quantification of IL-1β is normalized for GAPDH. Data are representative of three independent experiments (bars represent
the mean ± SEM; one-sample t test; *p < 0.05)
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exact mechanism as to how LRRK2 regulates PDE4
activity.
Taken together, our results provide a further evidence
supporting a PKA-LRRK2 axis in microglia cells, with
LRRK2 kinase controlling PKA activation through
PDE4; however, the molecular mechanism underlying
LRRK2-PDE4 functional interaction remains to be ex-
plored. In agreement with reduced NF-κB p50 phosphor-
ylation in the presence of hyperactive LRRK2, we found
that primary microglia isolated from LRRK2G2019S KI mice
exhibit increased inflammation compared to WT micro-
glia upon stimulation with α-Syn pffs. These observations
suggest that LRRK2 G2019S, as well as all other
pathological mutations that confer increased kinase
activity, favors the transition of microglia toward a
pro-inflammatory state, which, in turn, may result in an
exacerbated inflammation and neurodegeneration in
LRRK2-related PD patients. Supporting this hypothesis,
LRRK2 G2019S carriers exhibit higher levels of periph-
eral NF-κB-dependent inflammatory cytokines compared
to control subjects [42], and rats expressing LRRK2
G2019S display enhanced reactive microglia cells and
dopaminergic neurodegeneration after intracranial injec-
tion of AAV expressing α-Syn in the substantia nigra [43].
Conclusion
Overall, our findings indicate that LRRK2 kinase activity is
a negative regulator of PKA signaling and suggest that
PDE4 may be a novel LRRK2 effector protein in microglia.
Future studies directed at understanding LRRK2-dependent
regulation of PDE4 will offer a more defined scenario of
LRRK2 biology and pathobiology in these cells. In addition,
our observations suggest that LRRK2 G2019S may favor
the transition of microglia toward an overactive state, which
could widely contribute to the progression of the pathology
in LRRK2-related PD.
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